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Abstract
Platelets were mainly associated with coagulation and hemostasis; however, other biolog-
ical effects have been attributed to platelets, including angiogenesis, extracellular matrix 
synthesis, inflammation, and immune response. Dengue virus infection causes 200 mil-
lion cases of severe flu-like illness annually, escalating to life-threatening hemorrhagic 
fever or shock syndrome. Some hypotheses are postulated for immunopathogenesis of 
dengue, including antibody enhancement theory, T-cell activation of cross-reactive mem-
ory, and original antigenic sin. All hypotheses, to some extent, induce an overproduction 
or a skewed profile of cytokine release, giving rise to the term cytokine storm/cytokine 
tsunami. Although thrombocytopenia is typical of both mild and severe diseases, the 
mechanism triggering platelet reduction is incompletely understood. In dengue, plate-
lets are one of the major cell populations affected by direct and/or indirect mechanisms 
of infection. It is common to observe both thrombocytopenia and platelet dysfunction 
in dengue, both strongly related to the clinical outcome. Thus, platelets are frequently 
affected in dengue, either for alteration of their own functionality, for “silent transport” 
of virus, or as an anti-viral immune cell. In this way, we describe some of functional 
aspects of platelets on dengue, observing circulating mediators, intraplatelet proteins 
contents, morphology, activation markers, and ability to interact with dengue virus.
Keywords: dengue, platelets, thrombocytopenia, dysfunction of platelets, 
immunopathogenesis
1. Introduction
As the first cellular components accumulate at sites where there is vascular wall damage, 
platelets rapidly initiate events such as aggregation, exocytosis of granule constituents, adhe-
sion protein expression, cytokine, and others inflammatory mediator’s secretion and directly 
interact with endothelial cells and immune cells. In addition, they can perform the synthesis 
© 2018 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use,
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of new proteins through their complex post-transcription repertoire for post-activation trans-
lation, corroborating the existence of potential biological functions of platelets. In dengue, 
platelets are one of the major cell populations affected by direct and/or indirect mechanisms 
of infection.
1.1. An overview of immunopathogenesis of dengue
Dengue is one of the arboviruses transmitted by mosquitoes of the genus Aedes in a human-
mosquito-human cycle. It is endemic in more than 120 countries, where 50 to 100 million 
infections occur each year, which correspond to 55% of the world population live at risk 
of infection. Therefore, dengue has the greatest impact on public health worldwide with 
higher morbidity, albeit fortunately with low mortality rate [1]. The etiologic agent is the 
dengue virus (DENV), which has four antigenically distinct viral serotypes, the DENV 1 to 
4. DENVs share between 65 and 75% homology in their RNA sequences. As a member of 
the Flaviviridae family, the DENV consists of an envelope formed by a lipid bilayer derived 
from the endoplasmic reticulum of the host cell into which the envelope (E) and membrane 
(M) proteins are inserted. The viral particle is spherical in shape and approximately 50 nm 
in diameter. Below the viral envelope is a nucleocapsid composed of an icosahedral viral 
capsid formed by the capsid protein (C) and complexed to a single-stranded RNA molecule 
with positive polarity [2, 3]. Viral RNA DENV is approximately 10.7 Kb and is modified at its 
5‘ end by the addition of the cap structure but is devoid of the poly-A tail at the 3’ end and 
has a single open reading frame encoding a protein precursor polyprotein viral infection. 
This precursor protein is cleaved by both host cell proteases and viral protease, yielding 10 
proteins: structural C, pre-Membrane (prM)/ M, E, and nonstructural proteins (NS1, NS2A, 
NS2B, NS3, NS4A, NS4B, and NS5). The translated structural proteins are incorporated into 
the viral particles during their maturation, while the nonstructural proteins are involved 
in the replication and/ or assembly of the virions. The 3‘and 5’ noncoding regions are also 
important for viral replication [4–6].
Dengue fever is generally an acute disease, with a broad spectrum of clinical manifestations 
ranging from a clinically inapparent infection, an undifferentiated acute febrile illness, den-
gue fever (DF), to more severe forms, dengue hemorrhagic fever (DHF) and dengue shock 
syndrome (DSS). The first symptoms of DF and DHF are indistinguishable, but DHF is associ-
ated with hemorrhagic manifestations, plasma extravasation, and thrombocytopenia (counts 
below 150,000 platelets/mm3). Thrombocytopenia is not necessarily restricted to severe forms 
of dengue, since it is possible to see small bleeding in mild infections. DSS is distinguished 
from DHF by the presence of cardiovascular or other organs impairment, which occurs when 
loss of plasma to interstitial spaces results in shock. In general, DSS is a serious disease, with 
mortality rates of up to 20%, but may also be less than 1% in places with sufficient resources 
and with clinical experience [7, 8]. Symptomatic disease typically follows three phases: an 
initial febrile phase lasting 3 to 7 days; a critical phase around the defervescence during which 
complications may appear in some patients; and a spontaneous recovery phase [9].
A simplified categorization for the classification of dengue severity was proposed by the 
World Health Organization (WHO) in 2009 in which DHF and DSS were grouped as severe 
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dengue [1]. This classification was based on a multicenter study that treats the illness as a 
dynamic and systemic event. The new classification describes three sets of clinical signs and 
symptoms: (1) Dengue fever without signs of alarm (DF) characterized by nausea, vomit-
ing, rash, myalgia, headache, arthralgia, and positive tourniquet test with no signs bleed-
ing and leukopenia; (2) Dengue fever with warning signals (DFwWS) includes abdominal 
pain or tenderness, persistent vomiting, fluid accumulation, lethargy, agitation, hepatomeg-
aly (increase > 2 cm), elevated serum transaminases, and decreased platelet count; and (3) 
Severe Dengue Fever characterized by severe plasma extravasation, leading to shock and 
fluid accumulation, accompanied by respiratory discomfort, severe bleeding, and involve-
ment of organs such as the liver, central nervous system (with altered consciousness), heart, 
and other organs. This new classification proved to be more sensitive to the identification of 
severe forms, reducing the proportion of patients previously unclassifiable, which facilitated 
the clinical management of patients [10].
Briefly, immunopathogenesis of dengue is postulated by some hypotheses, including anti-
body enhancement theory [11, 12], T-cell activation of cross-reactive memory, and original 
antigenic sin [13]. All hypotheses, to some extent, induce an overproduction or a skewed pro-
file of cytokine release, giving rise to the term cytokine storm/cytokine tsunami [14].
The humoral response is mainly directed to the prM, E, and NS1 proteins, whereas in the 
cases of secondary infection, the response against NS3 and NS5 is observed [15, 16]. It is 
believed that a primary infection can create effective, lasting protection against reinfection by 
the same serotype, but triggers short-term cross-protection against the other serotypes [17]. 
Neutralization of infection by specific antibodies may occur by inhibiting the entry of the 
virus through its specific receptors into the target cell [18] or by inhibiting viral fusion into the 
target cell cytoplasm [19]. On the other hand, epidemiological studies suggest that homolo-
gous immunity may increase the severity of the disease during a subsequent infection by a 
heterologous serotype [11]. It is believed that low neutralizing antibodies, those that induce 
cross-reaction, produced in response to a previous serotype, contribute to the pathogenesis 
of dengue by promoting the entry of the virus through Fcγ receptors into myeloid cells, a 
phenomenon known as antibody-dependent infection (ADE) [20].
The role of T cells during dengue infection is still controversial, with studies supporting either 
an immunoprotective or immunopathological role [21]. Pioneer studies proposed that T cells 
have a detrimental role during secondary dengue infections in a process termed “original 
antigenic sin.” Based on this theory, cross-reactive T cells generated during primary infection, 
which recognize secondary-infected DENV serotype with low affinity, are poorly functional 
but prone to inducing immunopathology [13]. Thus, as cross-reactive memory, T cells are 
present in increased numbers and have a low activation threshold. They may outcompete their 
naïve subsets that have high affinity for secondary-infected serotype with an overall detrimen-
tal outcome for protective immunity [22]. Collectively, studies showed that dengue infection 
elicits a broad-specific T cell response that peaks around day 8–10 from fever onset [23, 24]. 
Dengue-specific CD8+ T cells are present at higher frequencies compared to their CD4+ coun-
terparts and preferentially target nonstructural proteins NS3, NS4b, and NS5, while CD4+ T 
cells are mainly directed toward the capsid envelope and the secreted protein NS1 [23].
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Moreover, studies have demonstrated that high concentrations of circulating cytokines, mainly 
released by T cells, monocytes, macrophages, and endothelial cells from patients, would be 
involved in the pathogenesis of dengue [24]. Initially, antiviral mechanisms of innate immune 
response mediated by interferons (IFNs), mainly produced by dendritic cells (DCs), mono-
cytes, macrophages, and natural killer (NKs) cells, are involved in initial infection control. 
The antiviral activity of type I IFNs (IFN-α/β) is initiated hours after infection and promotes 
inhibition of viral replication of infected cells, activation of the antiviral state by uninfected 
cells, and stimulation of the antiviral activity of the cells NK and CD8+ T lymphocytes [25, 26]. 
DENV proteins such as NS4B and NS5 have been shown to inhibit IFN-α/-β signaling [27–29]. 
However, in vitro and in vivo studies have demonstrated that DENV is capable of activating 
the production of IFN-α by human plasmacytoid dendritic cells (pDC) [30]. The IFN-γ (or 
IFN-type II), a cytokine involved with Th1 profile, is produced primarily by T lymphocytes, 
NK cells, and to a lesser extent by macrophages. The IFN-γ, like other IFNs, has an antiviral 
effect and promotes increased expression of human leukocyte antigen (HLA) class I and II 
molecules and stimulates antigen presenting and cytokine production by antigen-presenting 
cells (APCs) [31]. Kurane et al. reported higher levels of IFN-γ in the serum of patients with 
DHF and DF compared to healthy subjects, but IFN-γ levels were still higher after defer-
vescence in patients with DHF. According to the authors, these results suggest that IFN-γ 
would play an important role in infection control; however, high levels of this cytokine after 
defervescence, together with increased T cell activation, would contribute to the pathogenesis 
of DHF [32]. TNF-α is another cytokine that appears to play an important role in dengue. 
TNF-α is produced by mononuclear phagocytes, neutrophils, lymphocytes, and NK cells. The 
interaction of TNF-α and endothelial cells promotes induction of adhesion molecules, such 
as intracellular adhesion molecule-1 (ICAM-1), vascular cell adhesion molecule-1 (VCAM-
1), and E-selectin (E-CD62), being strongly involved in vascular damage, septic shock, and 
anti-tumor immunity [31]. In dengue, TNF-α appears to be involved in vascular damage, 
and authors observed an increased permeability and morphological changes in endothelial 
cells treated in vitro with TNF-α [33]. Studies have shown elevated plasmatic cytokines in 
dengue, such as IL-1β, IL-2, IL-4, IL-6, IL-7, IL-8, IL-10, IL-13, and IL-18, transforming growth 
factor-beta-receptor (TGF-β) [34–40]. Chaturvedi et al. reported that DF patients had higher 
levels of IFN-γ and IL-2, whereas the majority of DHF patients had IL-4, IL-6, and IL-10 eleva-
tion, on the 4th and 8th days of the disease, coinciding with the defervescence phase [41]. 
Pretreatment of monocytes/macrophages with Th2 profile cytokines (IL-4 or IL-13) increased 
the susceptibility of these cells to DENV infection [42]. Plasma levels of IL-10 were correlated 
with thrombocytopenia in dengue patients [34, 43]. High production of TNF-α, IL-1β, IL-12, 
IL-17, soluble IL-1 receptor type 1 protein (sST2), and tumor necrosis factor-related apopto-
sis-inducing ligand (sTRAIL), as well as apoptosis in DENV-infected monocyte/macrophages 
cultures, was also observed. It has been shown, therefore, that beneficial or deleterious bio-
markers may be present in dengue, regardless of the severity of the disease [44].
2. Thrombocytopenia and dysfunction of platelets in dengue
Reduced proliferative capacity of hematopoietic cells in bone marrow and/or increased destruc-
tion of platelets from peripheral blood are two main events associated with thrombocytopenia 
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[45–47]. Thrombocytopenia occurs when platelet formation (thrombopoiesis) is insufficient to 
balance physiological or pathological platelet consumption. Thrombocytopenia may occur in 
patients with either mild or severe cases of dengue infection and are associated in the early 
days of dengue infection [1]. The WHO guidelines for 2009 reaffirmed that a rapid decline or 
platelet count below 150,000/mm3 of blood are one of the indicators of clinical dengue worsen-
ing. Together, the functional disturbance associated with deregulation of the plasma quinine 
system is related with the immunopathogenesis of dengue [1, 48, 49].
2.1. Thrombocytopenia induced by bone marrow suppression, lysis of 
megakaryocytes and/or peripheral destruction of platelets
The kinetic observation of platelet counts in dengue patients showed a mild to moderate decrease 
in the 3rd to the 7th day, a significant decrease on day 4, reaching normal levels in the 8th or 9th 
day of the disease [50, 51]. Profound thrombocytopenia (nadir platelet count ≤20,000/mm3) was 
significantly more likely to detect early warning signs and longer hospital stays, but profound 
thrombocytopenia was not affected by DENV serotypes, coinfections, and secondary DENV 
infections [52]. However, a study involving 245 dengue patients showed no relationship between 
bleeding and platelet count, while 81 nonbleeding patients had a score below 20,000/mm3 [53]. 
In contrast, another study involving 225 dengue patients suggested that bleeding occurred more 
frequently in patients with PT [54]. Most clinical guidelines recommend platelet transfusion in 
patients with dengue who develop severe bleeding or platelet counts below 10–20,000/mm3. 
However, another study confirms that platelet transfusion does not prevent the development of 
severe bleeding or shorten coagulation time [55], and in severe dengue disease with hemorrhagic 
manifestations, the need for intensive care was not significantly associated with PT [52].
Previous published data indicated that DENV can induce thrombocytopenia through bone 
marrow suppression, lysis of megakaryocytes, and/or peripheral destruction of platelets [56]. 
Three main mechanisms seem to be involved, although partially explained, such as a direct 
lesion of progenitor cells by DENV, infected stromal cells, and modification of bone marrow 
regulation [51]. In fact, studies have shown a hypocellularity in bone marrow and inhibition 
of megakaryocyte maturation [51, 57]. In vitro studies using an adventitious reticular cell line, 
which are bone marrow stromal cells, incubated with DENV found DENV antigens in the 
perinuclear region of these cells [58]. These interactions lead to a modification in the cytokine 
profile produced in the bone marrow, as in the case of TGF-β capable of inhibiting the dif-
ferentiation of multipotent stem cells into megakaryocyte precursor cells, leading to inhibi-
tion of the cell differentiation process [59, 60]. Another cytokine, the thrombopoietin (TPO), 
regulates megakaryocytopoiesis and platelet production specifically through the activation of 
myeloproliferative leukemia virus oncogene (c-MPL), the TPO receptor [61, 62]. When plate-
let counts fall, circulating levels of TPO increase and may function as a useful indicator of 
megakaryocytopoiesis in dengue [63, 64]. Recently, authors showed that mice inoculated with 
recombinant DENV-envelope protein domain III (DENV-EIII)-suppressed megakaryopoiesis 
of progenitor cells from murine bone marrow and human cord blood in vitro, similarly to 
those observed with DENV infection. Additional analyses suggested that autophagy impair-
ment and apoptosis are involved in DENV-EIII-mediated suppression of megakaryopoiesis. 
Thus, these data suggest that, even without viral replication, the binding of DENV-EIII to the 
cell surface is sufficient to suppress megakaryopoiesis [65].
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Although several aspects of the pathogenesis of thrombocytopenia are still not clearly under-
stood, La Russa and Innis in 1995 demonstrated that DENV-induced bone marrow suppres-
sion depressed platelet synthesis [58]. In the same year, Wang et al. found that DENV-2 can 
bind to human platelets in the presence of virus-specific antibody, proposing an immune-
mediated clearance of platelets [66]. No infectious model that mimics DHF/DSS has yet been 
reported until Huang et al. described that the immunocompetent mice intravenous inoculated 
with DENV-2 developed transient thrombocytopenia and generate IgG class anti-platelet 
antibody. This was the first evidence of an association between anti-DENV immune response 
with cross-reactivity to platelets [67]. Falconar gave a strong contribution when identified a 
highly avid subclone monoclonal antibody MAb 1G5.4-A1-C3 from DENV-2 NS1 and oth-
ers anti-NS1 MAbs, which in addition of producing hemorrhage in mice, cross-reacted with 
human fibrinogen, thrombocytes, and endothelial cells, with known epitopes or active sites 
on human clotting factors and integrin/adhesin proteins present on these cells [68].
Previous study described a strong association between activation status of platelets and their 
destruction/depletion from circulation in febrile dengue patients [69]. Peripheral destruction 
of platelets can occur through the direct interaction of the virus in the platelet, as well as 
indirectly, since the infection leads to the formation of aggregates platelet-endothelial cells 
and platelets leukocytes or still to the secretion of anti-platelet antibodies and production of 
factors detrimental to platelets [56]. During dengue infection, cross-reactivity autoantibodies, 
including antiplatelet antibodies, are generated. In addition, anti-NS1 antibodies belong to 
the IgM class cross-react with platelets. This last one has the potential for activation of the cas-
cade complement system, leading to the induction of cell lysis and inhibition of platelet aggre-
gation [70, 71]. Notably, high anti-platelet IgM titers were detected in patients with DHF/DSS 
compared to DF. In accordance with high titers of IgM, serum from DHF/DSS patients causes 
more platelet lysis than the DF patient serum [71]. Autoantibodies against endothelial cells 
and blood coagulation molecules have also been described [72]. In fact, molecular mimicry 
between platelets, endothelial cells, or blood clotting molecules and NS1, prM, and E may 
explain the cross-reactivity of anti-NS1, anti-prM, or anti-E antibodies between host proteins 
and proteins. Cross-reactivity antibodies can cause platelet dysfunction, endothelial cell dam-
age, coagulation deficiencies, and activation of macrophages [73]. In addition, it has been rec-
ognized that platelet surface P-Selectin (P-CD62) activates integrins and mediates adhesion, 
aggregation, and secretion of mediators [74].
Among the soluble factors that play a role in the peripheral destruction of platelets, they 
include platelet-activating factor (PAF) [75], von Willebrand factor (vWF) [76], TNF-α, IL-1β 
[35], and IL-10 [34].
Platelet apoptosis and phagocytosis associated with high-serum TPO levels were significantly 
increased in dengue patients during the early stages of convalescence when compared to the 
late convalescence phase and in healthy volunteers. These results suggest that the abrupt 
drop in the number of platelets at the beginning of infection is outweighed by TPO-mediated 
thrombopoiesis [77]. Another study confirmed that platelets from patients exhibited classic 
signs of the apoptosis intrinsic pathway that include increased phosphatidylserine exposure, 
mitochondrial depolarization, and activation of caspase-9 and -3 [78].
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2.2. Dysfunction of platelets in dengue
Platelet activation is a phenomenon common during physiological dysbalance, such as dam-
age to blood vessels when in contact with components of the subendothelial matrix (collagen 
and vWF) [79], virus infections such as DENV and human immunodeficiency virus [80], hypo-
thermia [81], diabetes mellitus [82], and arterial thrombosis [83]. Moreover, some agonists 
involved in platelet activation include adenosine diphosphate (ADP), thromboxane A2 (TXA2), collagen, serotonin, epinephrine, and thrombin [84], in addition to pathogens and toxins [85].
During its activation, the platelets undergo a structural change process, in which the discoid 
cells undergo modifications in the cytoskeleton, disassembly of a ring of microtubules, resulting 
in an intermediate spherical shape. Next, actin polymerization and filopodia extension occur, 
causing the cell to acquire lamellar or dendritic morphology [86]. The major activated platelet 
receptors on interactions with other cells are glycoprotein GP IIb/IIIa (CD41/CD61) and P-CD62. 
The CD41/CD61 binds to adhesion proteins that contain the Arginine-Glycine-Asparagine pep-
tide sequence (RGD sequence), thus allowing the pooling and binding of activated platelets to 
leukocytes and endothelial cells via “bridge molecules,” such as fibrinogen [87]. P-selectin is a 
glycoprotein stored in platelet α-granules that is translocated to the surface and released in sus-
pension during platelet activation [85]. It is the main adhesion molecule responsible for platelet 
interaction with monocytes [85, 88–90], and circulating platelet-monocyte aggregates have been 
detected in dengue patients [89, 91]. As for the morphological and physiological profile of the 
platelets exposed to DENV-2, it was observed that there is platelet activation with increased 
expression of P-CD62 and fibrinogen binding. For morphological changes related to activation, 
the authors cited membrane architecture alterations, degranulation, the presence of filopodia, 
and dilation of the open canalicular system in platelets exposed to DENV-2 [92].
The events related to activation are not restricted to changes in morphology, having conse-
quences in several biological functions developed by the platelets. It is also observed exo-
cytosis of constituents of platelet granules, expression of adhesion proteins, and secretion 
of cytokines and other immunological mediators [93]. Activated platelets secrete mediators 
stored or synthesized in their granules, which act on several functions. In addition, during pla-
quetogenesis, megakaryocytes transfer platelet pre-mRNAs, such as tissue factor (TF, inflam-
matory mediator, and coagulation regulator) pre-mRNA to platelet, are processed to mature 
mRNA and translated into biologically active TF [94]. In this way, platelets have a complex 
post-transcriptional repertoire able to translate new proteins, a phenomenon evidenced in 
response to activation [95, 96]. Multiple pathways lead to platelet activation, including ago-
nists such as collagen, ADP, TXA2, epinephrine, serotonin, and thrombin, through interaction with receptors on platelet surface, leading to release of its granular content, increase of intra-
cellular Ca2+ levels, and activation of the fibrinogen receptor, αIIbβ3 integrin [97–100]. Studies 
have been reporting platelet dysfunction in dengue infections. In this context, suppression of 
platelet aggregation has been shown to occur along with an increased release of beta throm-
boglobulin (βTG) and Platelet Factor 4 (PF4/CXCL4) during the acute phase of DHF [101]. 
Assays using mononuclear leukocytes (MNLs) from healthy donors exposed to DENV-1 and 
2 release significantly greater amounts of PAF, TXB2, and Prostaglandin D2 (PGD2) than the donor not exposed to any DENV serotypes [102]. Previous data showed that TXB2 plasma 
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levels of DHF patients with shock decreased significantly than those of normal controls and 
DHF patients without shock patients, supposing that failure or inadequate TXB2 production may eventually lead to shock [103].
In addition to exerting an effector role, platelets influence the production of cytokines by 
peripheral mononuclear cells. Activated platelets exhibit anti-inflammatory properties related 
to the CD40 and CD40L interaction, leading to increased IL-10 production and inhibition of 
TNF-α by monocytes [104]. The authors also verified that the interaction of apoptotic mono-
cytes and platelets regulates the secretion of IL-10 through the recognition of platelet phos-
phatidylserine. It appears that IL-10 secretion requires only monocyte-platelet contact, but not 
phagocytosis, indicating that activated and apoptotic platelets aggregate to monocytes during 
infection [86]. Azeredo et al. found that IL-10 levels were correlated with low platelet counts 
[34]. Platelets are the major source of TGF-β1 in the human body [105]. One study has shown 
that circulating levels of TGF-β1 are significantly lower in patients with DHF than in controls 
[106]. Patients with immune thrombocytopenia have low levels of TGF-β1 in the circulation. 
However, after therapy to restore normal platelet count, their TGF-β1 levels return to levels 
found in healthy controls [107].
The innate immune system recognizes infection and changes in cellular homeostasis to initiate 
responses to clear pathogens and repair tissue damage. Toll-like receptors (TLRs) are part of 
the innate immune system, key players that modulate the inflammatory response and tumor 
dynamics. Many investigators have confirmed the expression of TLR1-9 both human and 
murine platelets [108]. Other major complex involved in these processes is the inflammasome, 
a multimeric protein complex that activates pro-caspase-1, which then proceeds to cleave 
multiple substrates including the pro-inflammatory cytokines IL-1β and IL-18 [109]. The 
presence of the nucleotide-binding domain leucine rich repeat containing protein (NLRP3) 
inflammasome in platelets activated after infection by DENV has been described, inducing the 
production of IL-1β by platelets and platelet-derived microparticles of dengue patients [89].
3. Deregulation of the platelets’ role in dengue: Hemostasis, site of 
virus, and immune cells
3.1. Deregulation between pro-and anticoagulant mechanisms in dengue
Hemostasis is a dynamic process in which physical and biochemical mechanisms promote 
blood clotting in a fast and regulated way [110]. Platelet adhesion and activation are mediated 
through the interactions between GP Ib-IX-V receptors with vWF and GP VI with subendothe-
lial collagen [111]. Alternatively, when the vascular endothelium is damaged, collagen sites are 
exposed, facilitating platelet adhesion at these specific sites. Platelets adhere to molecules in the 
subendothelial tissues at the lesion site, where they aggregate and interact with leukocytes and 
endothelial cells, thus initiating the coagulation cascade [112]. The coagulation factors present in 
the bloodstream are involved in a tightly controlled activation sequence, resulting in the forma-
tion of thrombin and subsequently fibrin. These factors circulate as zymogens, which require 
processing by proteolysis to be activated. According to the new model of blood clotting, it occurs 
in three overlapping stages: initiation phase, amplification phase, and propagation phase [113].
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During acute DENV infection, coagulation and fibrinolysis are activated, leading to coagula-
tion changes and fibrinolytic parameters that may lead to disseminated intravascular coagu-
lation (DIC) [114–116]. Funahara et al. reported that dengue patients with DIC had decreased 
platelet counts, transient prolongations of partial thromboplastin time (PTT) and prothrombin 
time (PT), and decreased levels of fibrinogen, prothrombin activity, factor VIII, antithrombin 
III, and plasminogen [117]. DIC leads to platelet activation, formation of fibrin, and deposi-
tion of small clots in the microcirculation, possibly contributing to organic failure. Notably, 
the consumption of clotting factors usually leads to paradoxical hemorrhagic disorders due to 
their consumption [118]. Later, it has been demonstrated that acute DIC that occurs in patients 
with DHF is associated with increased vascular permeability [117]. Thus, parameters such as 
platelet count, PTT, and PT present predictive value in the diagnosis of severe dengue [119].
The mechanisms that trigger DIC are mainly related to endothelial lesions and increased cir-
culating TF levels [118]. Several studies have suggested that increased TF expression plays 
an important role in the pathogenesis of dengue. Huerta-Zepeda et al. showed that DENV 
regulates levels of protease-activated receptor type 1 (PAR-1) and TF in the activated endo-
thelium [120]. These data are reinforced by the evidence of increased plasma levels of TF in 
dengue patients, and the expression of TF in monocytes was inversely correlated with platelet 
counts [121, 122]. Our previous data found that dengue patients with a good outcome showed 
decreased circulating levels of TF than those with a poor outcome (Severe). Similarly to TF, 
tissue factor pathway inhibitor (TFPI) levels were significantly lower in patients with a good 
outcome, but increased TFPI plasma levels were observed in severe patients. We also demon-
strated that TF and TFPI levels were significantly higher among patients with hemorrhagic 
manifestations. In addition, DENV-1 or -2 patients were more likely to have increased levels 
of TF than DENV-4 patients [123]. Activation of PAR-1 is accompanied by positive regula-
tion of adhesion molecules and production of proinflammatory cytokines [124]. The coagula-
tion enzymes generated in DENV infection can activate PAR-1 receptors, thus increasing the 
increase of pro-inflammatory cytokines and leukocyte migration. These cytokines, along with 
coagulation enzymes (and vice versa), perpetuate the inflammatory response, which promotes 
increased interaction between activated monocytes, activated endothelial cells, and platelets. 
The result is a convergence of signals that lead to exacerbated expression of TF. Therefore, 
the coagulation and inflammation processes are closely related and establish a bidirectional 
relationship mediated by the activation of PARs [125].
Since hemostasis depends on the balance between coagulation and fibrinolysis, Huang 
et al. evaluated some coagulation parameters (platelet count and PTT) as well as fibrinolytic 
parameters (tPA and PAI-1) in patients with DHF and DF. Patients with DF show thrombo-
cytopenia, PTT prolongation, and increased tPA levels, indicating coagulation activation and 
fibrinolysis. However, the parameters used indicated much more severe activation of coagu-
lation and fibrinolysis in patients with DHF. In the convalescent phase, there is an increase in 
PAI-1 and platelet counts with concomitant decline in tPA levels and normalization of PTT, 
both in patients with DHF and in DF. According to the authors, the activation of coagulation 
and fibrinolysis during the acute phase of DENV infection is compensated by the increase of 
platelets and PAI-1 during the convalescence phase. These results suggest that the degree of 
activation of coagulation and fibrinolysis induced during dengue infection is associated with 
the severity of the disease [114].
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3.2. Platelets as target cells for DENV replication
Platelets contain receptors related to DENV entry, such as Dendritic cell-specific intercellu-
lar adhesion molecule-3-grabbing nonintegrin (DC-SIGN) [126]. In vitro infection by DENV 
induces activation, mitochondrial dysfunction, and platelet apoptosis through mechanisms 
dependent on the DC-SIGN receptor [127]. A study detected DENV RNA by conventional 
reverse transcription polymerase chain reaction (RT-PCR) and DENV-like particles by elec-
tron microscopy in patients’ platelets [128] and later confirmed the presence of viral antigen 
in platelets by immunofluorescence and confocal microscopy [129]. It is still unclear whether 
platelets are involved in the spread of viral infection. Recent data from our group have con-
firmed the in vitro interaction of DENV with platelets, leading to subsequent morphological 
modifications characteristic of platelet activation, such as presence of membrane extensions 
(filopodia), loss of cytoplasmic content and dilation of the membrane system [Azamor and 
Oliveira submitted]. A study using blood cells from dengue patients and rhesus monkeys 
experimentally infected revealed DENV antigens present in vesicles of varying sizes and often 
in nuclear cells like platelets. The DENV RNA was detected in a highly enriched population 
of rhesus platelet-characteristic CD61+ cells in the acute phase of infection, indicating that the 
virus may be directly linked to dysfunction and low platelet counts [130]. More recent and for 
the first time, authors demonstrated in fact that platelets directly bind DENV saturably and 
produce infectious virus. Interestingly, at 37 and 25°C, platelets replicated the positive sense 
single-stranded RNA genome of DENV by up to ∼4-fold over 7 days, with production of viral 
NS1 protein. The infectivity of DENV intrinsically decayed in vitro, which was moderated by 
platelet-mediated generation of viable progeny. DC-SIGN and heparan sulfate proteoglycan 
(HSP) were implicated as coreceptors because only the combination of anti-DC-SIGN and 
low-molecular-weight heparin prevented binding. Thus, expression of antigen encoded by 
DENV is a novel consideration in the pathogen-induced thrombocytopenia mechanism [131]. 
Finally, very recent analyze revealed that DENV works as the primary driver of platelet acti-
vation and also enters and replicates in platelets but does not result in a productive infection 
of platelets. Moreover, the DENV-exposed/DENV antigen-positive platelets associate with 
CD14+CD16+ monocytes may mediate platelet clearance from the circulation [132].
3.3. Platelets as immune cells
Platelets, when interacting physically with leukocytes and endothelial cells, act as a kind of 
signaling of inflammation and immune response. When stimulated and activated, these cells 
initiate events, such as aggregation, formation of microparticles and exosomes [133], expres-
sion of adhesion proteins and receptors, and exocytosis of constituents present in their gran-
ules [76]. Exocytosis of α-dense granules and lysosomes releases cytokines and biological 
mediators with various immunological and inflammatory functions. In addition to secret-
ing soluble mediators, platelets express receptors involved with the immune defense, such 
as Fc receptors that are able to recognize IgG, IgE, and IgA classes. These receptors may 
confer rudimentary antibacterial activities of platelets, such as the secretion of antimicrobial 
peptides and phagocytosis against direct interaction with bacteria, viruses, protozoa, or hel-
minths. These immunoreceptors influence platelet adhesion activity through the modulation 
of integrin production [76]. Another set of receptors present on platelets with immunological 
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action is that of TLRs. Among the 10 TLRs identified in humans, six are expressed in plate-
lets, the TLR-1, -2, -4, -6, -8, and -9. TLR-4 has been shown to modulate sepsis and inducer of 
TNF-α in vivo [134]. TLR-2 modulates IL-1β RNA processing, inducing the production of IFN 
type 1 and other inflammatory cytokines [135]. The set of inflammatory, hemostatic, angio-
genic, and coagulators reactions are multicellular events that include chemotaxis, adhesion, 
interactions between leukocytes, endothelial cells, and platelets in the walls of blood vessels. 
Platelets contribute to these interactions through secretion of adhesion proteins and regu-
lation of chemokine synthesis by leukocytes and endothelial cells [136]. Molecules such as 
IL-1β, PAF, and P-CD62 stand out as the main mediators derived from platelets, able of acti-
vating leukocytes [137]. Studies have shown that activated platelets induce increased IL-10 
expression and decreased TNF-α by monocytes [101].
Several studies have indicated that DENV infection leads to the activation of endothelial cells, 
which increase the expression on the surface of the E-CD62 molecule. E-CD62, as well as 
P-CD62, are adhesion molecules responsible for platelet adhesion to endothelial cells [113, 
138]. In addition to the endothelium, P-CD62 is expressed on the surface of activated platelets, 
promoting their interaction with leukocytes and formation of aggregates between platelets 
and monocytes and/ or neutrophils in primates [139]. Platelet-monocyte aggregates are also 
observed in DENV-infected patients, leading to the synthesis of IL-1β, CXCL8/ IL-8, CCL4/ 
MCP-1, and IL-10 by monocytes [107]. The formation of cell aggregates results in an increase 
in the inflammatory response in dengue, as well as contributing to the generation of thrombo-
cytopenia both by the physical retention of cells, by lowering the number of circulating cells 
and by the induction of cell death [140]. In 1992, Butthep et al. showed that platelets, as well 
as neutrophils and lymphocytes, preferentially bind to endothelial cells exposed to DENV, 
compared to cells not exposed to DENV. It has been suggested that increased platelet endo-
thelial cell binding may contribute to thrombocytopenia in dengue patients [141]. Protein 
disulfide isomerase (PDI), an endoplasmic reticular protein, is located on the surface of plate-
lets [142] and is involved in the regulation of integrin-mediated platelet aggregation, since 
anti-PDI antibodies block platelet adhesion and aggregation [143]. Previous studies have 
demonstrated that platelet surface PDI can be recognized by anti-NS1 antibodies. Rachman 
and co-workers observed a similar kinetic profile between anti-NS1 and PDI antibodies [144]. 
PDI enzyme activity and platelet aggregation were reduced with anti-NS1 action. Amino 
acid residues 311–330 (P311–330) of NS1 represent an epitope that shares sequence homology 
with the PDI thiorretoxin domain [145]. In contrast, although the serum of dengue patients 
inhibits platelet aggregation, there is no correlation between anti-NS1 and PDI with platelet 
aggregation dysfunction, suggesting that other mechanisms may be involved in the inhibition 
of platelet aggregation [144, 145]. Platelets are responsible for the maintenance of vascular 
integrity due to the constitutive release of pro-angiogenic cytokines and growth factors. The 
α-granule-derived molecules such as angiopoietin-1, α and β-catenins, and PAF bind to spe-
cific receptors on the surface of endothelial cells, causing intracellular signaling that stabilizes 
the intercellular adhesion junctions [146]. Angiopoietins, key molecules of vascular integrity, 
are also stored in platelets. Both dengue-associated thrombocytopenia and endothelial activa-
tion are associated with an imbalance in the ratio of angiopoietin-2: angiopoietin-1 plasmatic. 
Studies have shown that there is an inverse correlation between angiopoietin-1 and plasma 
extravasation markers but a direct correlation between angiopoietin-2 and markers of plasma 
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extravasation in patients with DHF/DSS [147]. Hottz et al. demonstrated that DENV-infected 
patients who showed signs of increased vascular permeability demonstrated a higher per-
centage of platelets and platelet-derived microparticles (MP) expressing IL-1β and caspase-1 
activator compared to patients who had no evidence change in vascular permeability. These 
results were confirmed in experiments in which platelet-derived MPs exposed to DENV 
caused an increase in the permeability of endothelial cells that was blocked by IL-1Ra [127].
More recently, proteome analysis related to platelet activating signaling from platelets from 
dengue patients demonstrated an increase of PAR-4 (F2RL3), G protein subunits (GNA12 and 
GNA14), and p38 MAPK (MAPK14), in which potentially contributing to increased platelet 
activation during dengue infection. Moreover, dengue patients had increased P-CD62 sur-
face expression on platelets from patients presenting dengue with warning signs and severe 
dengue syndromes compared to mild dengue. In agreement, they observed exhaustion of 
the granule-stored chemokine PF4/CXCL4 in platelets from patients with dengue [148], simi-
larly to another study reported that patients with severe dengue have lower levels of PF4/
CXCL4 in plasma when compared to mild dengue patients [149].
4. Conclusion
Platelets are cellular fragments derived from hematopoietic precursors megakaryocytes, pri-
marily associated with coagulation and hemostasis and also with inflammation, immune 
response, angiogenesis, and extracellular matrix synthesis. In fact, platelets contain several 
preformed molecules, large amounts of mRNA, and the packaged translational process 
required to synthesize new biologically active proteins, including growth factors, cytokines, 
and chemokines. Platelets are one of the major cell populations affected in dengue, once both 
thrombocytopenia and platelet dysfunction are common manifestations of infection and 
strongly related to the patient’s clinical outcome. Dysfunction of platelets is implicated in 
prothrombotic complications associated with severe cases of dengue. Thus, platelets could 
be considered cells that are active against the anti-DENV immune response, and therefore, 
thrombocytopenia is a key prognostic factor in the immunopathogenesis of dengue.
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ADE antibody-dependent infection
IFNs interferons
NKs natural killer cells
pDC plasmacytoid dendritic cells
DCs dendritic cells
IFN-α/β type I IFNs
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